Jul 25, 2011 by Brian Orelli, PhDBristol-Myers' Acquisition Could Pay for ItselfIt will gain access to potential milestones.
Jul 22, 2011 by Brian Orelli, PhDThat's All the Melanoma Market Is Worth?BioSante licenses out its melanoma vaccine for $100,000.
Jul 22, 2011 by Brian Orelli, PhDIt's How You Finish That MattersHuman Genome Sciences had better hope the saying is true for lupus drug Benlysta.
Jul 21, 2011 by Brian Orelli, PhDKeep an Eye on Biotech Partners' EarningsNovartis' earnings are important for Momenta and Vanda.
Jul 21, 2011 by Brian Orelli, PhDAMAG-Allos, a Match Made in NecessityCommercial challenges make strange bedfellows.
Jul 20, 2011 by Brian Orelli, PhDFirst in Class Isn't the Sweetest PositionBristol and AzstraZeneca's diabetes drug dapagliflozin runs into trouble.
Jul 19, 2011 by Brian Orelli, PhDJ&J: Better, but Not BestA decent-looking quarter, but a turnaround could still take awhile.
Jul 19, 2011 by Brian Orelli, PhDFree Cash, But Be CarefulNabi trades below today's cash, but maybe not next years.
Jul 18, 2011 by Brian Orelli, PhDThe Tale of 2 Drug HandbacksBristol-Myers returns another drug to Exelixis.
Jul 18, 2011 by Brian Orelli, PhDA $3.6 Billion Franchise at StakeAmgen and Teva settle their patent dispute.
Jul 15, 2011 by Brian Orelli, PhDSeattle Genetics Will Work It OutThis isn't the NFL labor negotiations.
Jul 15, 2011 by Brian Orelli, PhDVical Transplants Some FirepowerA licensing deal with Astellas gives the company a shot in the arm.
Jul 14, 2011 by Brian Orelli, PhDGood Data, but Lots of CompetitionRegeneron's sarilumab passes a phase 2b trial.
Jul 12, 2011 by Brian Orelli, PhDThat's One Expensive BiTEAmgen licenses Micromet's BiTE antibody technology.
Jul 12, 2011 by Brian Orelli, PhDDucks in Order; Now Let's See Some DataSequenom sets up a supply agreement with Illumina.
Jul 11, 2011 by Brian Orelli, PhDThe Big Bet on Seattle GeneticsMany drugs -- but only one is important in the near term.
Jul 8, 2011 by Brian Orelli, PhDLet's Just Hope For No More FDA SurprisesDespite the government's worries, Bydureon doesn't cause heart issues.
